These are the first targets to be selected for advancement in the strategic collaboration established last year between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research.
“We’re pleased that Abbott has elected to move forward with these targets,” said Kathy Ordonez, president of Celera Genomics. “This represents an important milestone toward our goal of working with partners to develop a pipeline of small molecule and antibody based-targeted therapies derived from discoveries made on our proteomics platform.”